THE APEX TIMES
Kentucky-led trial findings suggest CBD and THC combination may reduce agitation in late-stage dementia patients
Researchers connected to the University of Kentucky’s Sanders-Brown Center on Aging participated in a study reporting that a cannabidiol and tetrahydrocannabinol combination improved quality-of-life outcomes for people with late-stage dementia, particularly by reducing agitation.
A new research report highlighted by Kentucky media says a combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) may help improve quality-of-life measures for people living with late-stage dementia, with a focus on reducing agitation.
The article, published Aug. 4 by Kentucky Lantern, says Kentucky participated as a trial site through the University of Kentucky’s Sanders-Brown Center on Aging. Dr. Greg Jicha, identified by the outlet as the center’s director of clinical trials, is quoted describing the CBD and THC combination as beneficial for patients in late-stage disease, where agitation and distress can worsen as dementia progresses.
Kentucky Lantern’s report characterizes the study results as showing improvements in quality-of-life outcomes, and it specifically points to agitation as an area where patients may experience less distress. The outlet describes the CBD and THC combination as being administered to patients as part of the study and frames the findings around late-stage dementia, a stage associated with increased care needs and higher caregiver burden.
The report does not describe, in the portion summarized for publication, the full clinical dosing schedule, the size of the study, the precise symptom scales used, or the duration of follow-up. It also does not detail the full safety profile in the way a peer-reviewed trial report would, including the rate and type of side effects observed in patients.
Dr. Jicha’s comments are presented as part of the center’s clinical-trials work, and the article ties the research to Kentucky’s role in conducting or supporting the trial. For families and long-term-care settings, the reported focus on agitation is significant because agitation can drive higher staffing demands, more frequent medication adjustments, and increased risk of harm for patients and caregivers when behaviors escalate.
Regulatory and treatment decisions will still depend on the full study record, including eligibility criteria, outcome measures, and safety results. Any use of CBD and THC combinations for dementia care would also be subject to state and federal rules governing medical products, prescribing practices, and the availability of study-grade or approved formulations.
Why It Matters
- Agitation is a commonly reported, high-impact symptom in late-stage dementia, affecting patient comfort and care resources in long-term-care and home settings.
- If the findings are confirmed in the full trial record, they could influence future clinical research and treatment discussions for late-stage dementia symptom management.
- Any move toward broader use would require attention to safety findings, dosing details, and product regulation, which are not fully detailed in the report’s summary.
- Because Kentucky participated in the trial, the results may heighten local and statewide interest in dementia clinical research and translational medicine.
Key Facts
- Kentucky Lantern reported on Aug. 4 that a study found a CBD and THC combination may improve quality-of-life outcomes for late-stage dementia patients.
- The report says Kentucky participated as a trial site through the University of Kentucky’s Sanders-Brown Center on Aging.
- Dr. Greg Jicha, the center’s director of clinical trials, is quoted in the report discussing the findings.
- The outlet emphasizes reduced agitation as a key quality-of-life improvement in late-stage dementia.
- The report frames the results around patients receiving the CBD and THC combination during the study.